UCB - Cash And Equivalent


UCB reported EUR1.57B in Cash and Equivalent for its fiscal semester ending in December of 2024.





Cash And Equivalent Change Date
Alcon AG USD 1.58B 80M Mar/2026
Almirall EUR 337.77M 14.83M Dec/2025
Amarin USD 156.51M 12.95M Sep/2026
argenx SE USD 2.6B 984M Sep/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Bayer EUR 4.29B 1.44B Jun/2026
Genmab DKK 1.5B 18M Jun/2026
GlaxoSmithKline GBP 3.1B 337M Jun/2026
GRIFOLS EUR 513M 189M Jun/2026
Hikma Pharmaceutical USD 217M 19M Dec/2025
Lakefront Biotherapeutics EUR 135.95M 69.15M Jun/2026
Lonza CHF 719M 188M Dec/2025
Merck EUR 2.74B 415M Mar/2026
Novartis USD 7.62B 739M Jun/2026
Orion EUR 144.3M 55M Sep/2026
Recordati EUR 391.38M 10.92M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
UCB EUR 1.57B 1.14B Dec/2024
Unibail Rodamco EUR 5.29B 668.7M Dec/2024